Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Drawing on the film Wonder, this article examines how a narrative of community acceptance offers sustaining relationships for people with unusual facial appearance.
AMA J Ethics. 2019;21(11):E1003-1008. doi:
10.1001/amajethics.2019.1003.
Two pediatric cases highlight risks of prolonging anesthetic exposure for training purposes and prompt questions about influences of surgical training on outcomes.
AMA J Ethics. 2020;22(4):E267-275. doi:
10.1001/amajethics.2020.267.
Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported.
AMA J Ethics. 2019;21(11):E968-973. doi:
10.1001/amajethics.2019.968.